Luka Space Health Care

Just about Health Care and Medical Reviews

You are here: Home - Germany


Tag Archives: Germany

Beer May Help Prevent Breast And Prostate Cancer

We’ve all heard the story about red wine and how a glass a day (or something like that) can prevent high blood pressure and heart attacks and all that jazz, but no one seems to want to talk about the potential health benefits of beer. While wine is seen as the “healthy” alcoholic choice because of its antioxidants, beer is seen as a fattening, unhealthy drink. It does have its own type of belly, after all. But beer might actually be healthier than is commonly perceived, our next several Beer Facts OTW will discuss the potential health benefits of beer, and we’ll start right now with possibility that beer may help prevent breast and prostate cancer.

To begin, let’s talk a little bit about how cancer is formed in the prostates of men and the breasts of women. In either case, it seems that overactive hormones are to blame. There have been studies that show that increased levels of testosterone in bloodstream are associated with the formation of prostate cancer. Similarly, high levels of estrogen in women are known to elevate the chances of a tumor forming in the breast tissue. Why are these hormones, that appeared to be so harmless when we first learned about them in Sex Ed, the main culprits in a couple of the most feared types of cancer? Not due to any fault of their own. In fact, they’re just doing their job – promoting cell growth. In men, testosterone helps with the growth of hair a muscle, while in women, estrogen is involved in things like uterine growth. When something goes wrong and your body fails to automatically balance these levels of hormones is when you start to get into trouble. That’s when estrogen calls for the production of too much breast tissue, or testosterone overworks the prostate glands. In both cases, rapid cell growth leads to a tumor.

What does beer have to do with any of this? If you know anything about beer, you know that one of the most important ingredients is hops – that cute little green pinecone-esque seed thingy that makes beer taste oh so delicious. Well it turns out that there’s a naturally-occurring chemical compound in hops called xanthohumol. After doing a whole bunch of tests on the chemical in both rats and humans, German scientists were able to conclude that xanthohumol blocks the effects of both testosterone and estrogen, meaning any problems that are caused by abnormal hormone levels could potentially be avoided. The whole chemistry behind it is super confusing, but as far as I can tell the xanthohumol attaches itself to the hormone and acts like some sort of mute button, preventing the hormone from communicating with cells, thus avoiding the problem of the kind of hyperactive cell activity that would lead to cancer.

The information coming out of these studies so far is extremely exciting, but the scientists over at the Division of Epigenomics and Cancer Risk Factors in Heildelberg, Germany are still hard at work trying to figure out whether or not that beer you’re holding could actually save your life. It could be a while until they find out for certain, but I’m already pretty convinced.

So next time your wife or girlfriend bugs you for having that beer before bed, tell her you’re only doing it to stay healthy so you can be with her longer. While you’re at it, get her to have one too. We wouldn’t want cancer to take away your favorite part of her body.

Germany Dental Devices Market Analysis And Forecasts To 2015

Browse Complete Report: Germany Dental Devices Market
http://www.reportsnreports.com/reports/14858-germany-dental-devices-market-analysis-and-forecasts-to-2015.html

This report is an essential source for in-depth information and data relating to the Germany dental devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the dental devices market in Germany.

Scope
The report provides dental devices market information broken down into detailed categories and segments in Germany.
Total revenues, products sold, end users, and average pricing.
Market shares of all the key competitors. Key pipeline products that are set to shape the market, broken down by sector.
Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
Key mergers and acquisitions, partnerships, private equity investments and IPOs.
Customer, hospitals and physicians data.

Reasons to buy
Gain a strong understanding of the dental devices market in Germany.
Evaluate and compare the attractiveness of the market in the country.
Identify growth segments and opportunities in each industry sector within the country.
Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
Analyze the competitiveness of the market in the country and identify hotspots.
Develop strategies based on the latest product, brand, expansion and research and development news in the country.
Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Buy Now: Market Research
Browse All: Dental Devices Market
Browse: Germany Market

Related Reports:
Global Dental Devices Market Analysis and Forecasts to 2015
Japan Dental Devices Market Analysis and Forecasts to 2015
Canada Dental Devices Market Analysis and Forecasts to 2015

Tags:

Historical Health And Fitness Trends

Many people nowadays may probably be living a toxic and always busy lifestyle. However, this should not hinder any one from targeting a goal to be healthy and fit. In fact, there are numerous health spas and gyms that can be found everywhere offering services and facilities for people who want to be fit and healthy. Included in the services are popular trends in health and fitness that aids in the overall improvement of a persons well being.

During the early part of the 20th century in Germany, Joseph Pilates has developed one of todays hottest trends in health and fitness. The program of Pilates entails improving the central postural muscles which are essential in balancing the body and in supporting the spine. Also, Pilates is aimed at teaching proper breathing, aligning the spine and strengthening the muscles. In brief, Pilates works on the good physical and mental condition of the body.

In America, at the height of economic depression during the 1920s, the art of pole dancing was developed. Pole fitness is one of the forms of this pole dance which some people nowadays are utilizing for their health and fitness regime. A pole is used in firming and conditioning the arms, thighs, abs and back. The program incorporates combination of jazz, ballet, acrobat and gymnastics.

In the early part of 1970s, Hot Yoga or Bikram Yoga was developed by Bikram Choudhury. This synthesized form of the traditional yoga is focused on the bodys overall wellness. Hot yoga involves deep stretching to prevent injury and relieve stress. Every muscle, organ and joint of the body is stimulated and restored its healthy condition. In this form of yoga, a participant is required to stay warm by wearing layers of clothing or switching a rooms heat on.

During the 1990s in Colombia, Zumba was developed by the choreographer Alberto Perez. This physical fitness program combines international and Latin music and dance for a more enjoyable exercise. Aside from being entertaining, Zumba is perfect in polishing the bodys shape as it helps boost metabolism or the rate of burning calories in the body. Balance and posture are also improved with the programs basic steps.

Kettlebells, also called girya are exercise tools looking like a cannon ball with handle of a large iron bowl with handle. They surprisingly make a person on a workout session to feel lively and comfortable while exercising. This revolutionary equipment helps improve the muscle mass in many key areas of the body such as back, thighs and abs. This fitness program is also effective in increasing the fat burning rate of the body for a slim waist.

Speaking of burning calories, another fitness trend called Spinning is utilized to effectively shed 900 calories. In fact, Spinning is one of the intense workouts for fitness. Spinning involves loud and thumping music while sweating out on a stationary bike.

Tai-chi is a fitness trend popular which has its origin from the Far East. This workout is executed on a standing position while moving in a very slow and methodical fashion, the body is twisted and the limbs are raised or lowered. A soothing and quiet music is used while doing this program.

Stimulating The Bodys Defenses To Fight Ovarian Cancer

Comediennes such as Gilda Radner and Madeline Kahn, Oscar-winning actresses like Loretta Young and Sandy Dennis, singers Laura Nyro and Dinah Shore, actor Pierce Brosnans wife Cassandra Harris, actress Jessica Tandy, former Connecticut governor Ella Grasso, and Martin Luther Kings wife Coretta Scott King all died of ovarian cancer. Its not just celebrities, politicians or movie stars, who are stricken with ovarian cancer. One in every 55 U.S. women is at risk for ovarian cancer. The American Cancer Society estimates about 22,000 new cases of ovarian cancer will be diagnosed. More than 16,000 women will die because the symptoms are often subtle, and her doctor did not recognize the symptoms soon enough. It is the leading cause of death from gynecologic malignancies, and the fifth leading cause of cancer deaths among women.

Silent and undetected, this cancer often spreads beyond the ovary or ovaries into the abdominal cavity, or by the final stage, into other body organs such as the liver or lungs. Family doctors often fail to properly diagnose The Silent Killer until it is too late. Last August, University of California Davis researchers reported 40 percent of women told their doctors about their symptoms for as long as a year before they were correctly diagnosed. A British survey discovered 75 percent of family doctors believed symptoms are only present during the advanced stages of the cancer. By the time women are diagnosed for ovarian cancer, 40 to 50 percent of the patients are in the advanced stage, where there is little hope for survival.

Less than one-half the women diagnosed with ovarian cancer will live five years. About 10 to 14 percent live beyond five years after their diagnosis. Their choices have been limited, mainly reserved to variations of chemotherapy drugs or a new way to delivery the drug. The general public is often unaware of the side effects ovarian cancer patients suffer during chemotherapy. In mid March, the U.S. Food and Drug Administration criticized the safety profile of Eli Lillys Gemzar for ovarian cancer patients, saying the 2.8 months increased survival seen in studies of patients taking the drug wasnt enough to offset the treatments increased toxicity which included anemia, neutropenia (a blood disorder) and thrombocytopenia (reduced platelets in the blood). Presently used first-line treatments for ovarian cancer patients include Cisplatin, with associated side effects such as nerve, kidney and/or ear damage, Carboplatin (side effects: nerve damage in the arms and/or legs, joint pain, and/or thrombocytopenia), Paclitaxel (neurotoxicity), or Melphalan, with side effects which include irreversible bone marrow failure, bone marrow suppression).

A woman stricken with ovarian cancer faces first surgery, then chemotherapy. Recent widespread press heralding a new development in treating ovarian cancer, intra-abdominal or intraperitoneal chemotherapy, is just that: more chemotherapy. The belly bath, as it has been nicknamed by some television reporters, it has been highly praised because the treatment can extend life by about 16 months more than regular chemotherapy. The results were first published in the prestigious New England Journal of Medicine in December 2005. Most news reports failed to mention that only 40 percent of the women treated with the belly bath were able to complete all six cycles. Why? The therapy relies upon infusions of Paclitaxel and Cisplatin (see side effects in the previous paragraph). According to Dr. Robert Edwards, research director of the Magee-Womens Gynecologic Cancer in Pittsburgh, Many women dont feel well enough to work for the duration of the intra-abdominal (therapy). Some patients, such as Cindy Pakalnis of Marshall (Pennsylvania) have called the treatments grueling.

The unsolved problem of chemotherapy is the reduction in the quality of life. While some life extension has been proven, the patients life deteriorates. Many patients struggle with balancing the loss in quality of life with the rigors of the therapy. Researchers are actively pursuing new directions that may some day provide new hope for the ovarian cancer patient. A University of Minnesota research study has suggested the use of thalidomide, which would be used in conjunction with chemotherapy, as a prospective means of increasing the likelihood of remission. Minnesota cancer researcher Dr. Levi Downs explained, It prevents the tumor from making new blood vessels. Without new blood vessels, the tumor cant sufficiently feed new cells, so the cancer cant grow. His randomized trial was small with only 65 patients (only 28 took thalidomide), and more testing will certainly be required.

New Hope for Ovarian Cancer Patients?

One promising technology that has been developed over the past decade is OvaRex MAb. It was developed by ViRexx Medical Corp., an Edmonton-based company, which trades on the American Stock Exchange (ticker symbol: REX) and on the Toronto Stock Exchange (ticker symbol: VIR). Now licensed to Unither Pharmaceuticals, a wholly owned subsidiary of United Therapeutics (NASDAQ: UTHR), OvaRex MAb is currently undergoing two identical Phase III trials at about 64 research centers across the United States. One trial has completed enrollment, according to a mid December news release issued by ViRexx Medical Corp.

We spoke with ViRexx Medical Corps Chief Executive Officer, Dr. Tyrrell who was the Dean of the Faculty of Medicine and Dentistry at the University of Alberta and the Director of the Glaxo Heritage Research Institute. OvaRex MAb is our lead candidate for the treatment of ovarian cancer, and is an intravenous infusion of a monoclonal antibody, he said. Monoclonal antibodies are a new breed of biotech drugs that are extremely specific; that is, each antibody binds to only one particular antigen. In the case of OvaRex MAb, it is a monoclonal antibody that binds specifically to the CA-125 antigen. Dr. Tyrrell added, The treatment doesnt take long, and is given every 4 weeks for the first 3 injections, and then once every 3 months until the patient relapses.

Dr. Tyrrell talked about the current Phase III studies, The trials are ongoing. All of the patients have successfully completed their surgery and front-line chemotherapy and are now in what we call the watchful waiting period. It is in this phase that we treat the patients with OvaRex MAb with the hopes of increasing the time to disease relapse. He explained the recurrence rate is very high in the stage III / IV late forms of ovarian cancer, with a time to relapse of about 10.4 months. Patients who have turned to OvaRex hope to delay that relapse. Tyrrell noted, In the original study, the average time to relapse was delayed by about 14 months. If we can achieve that difference or better in the current Phase III trials, it would be a major advance for the treatment of ovarian cancer. He expects an analysis of the current OvaRex MAb studies to be completed by the second or third quarter of 2007.

What makes OvaRex MAb different from other immunotherapeutic treatments is, instead of attacking the bodys cancerous cells directly, the monoclonal antibody targets the cancerous antigen in circulation. Some believe it helps retrain the bodys immune system to fight the ovarian cancer cells. The mechanism that reportedly has made OvaRex MAb effective is how it alerts the body to recognize and fight the CA-125.

ViRexx has addressed the tolerance problem a body suffers when it has become inflicted with a malignant tumor. The hypothesis behind the tolerance issue is that the body fails to recognize the CA-125 antigen as harmful. Introducing a foreign antibody, in this case the mouse antibody against CA125, the bodys defense systems are awakened to the ovarian cancer cells. This begins a chain reaction alerting the immune system to battle the invading antibody CA125 complex. The bodys defense systems are reprogrammed to attack the CA-125 antigen and seek to destroy it. Along with that destruction comes the attempt of the immune response to eliminate the cancerous cells from the body.

As with many pioneering scientific breakthroughs, serendipity is what lies behind the OvaRex MAb story. As one technology was being developed, another the murine monoclonal antibody treatment for ovarian cancer came about by accident. We talked to its inventor, Dr. Antoine Noujaim, about the biotech drugs roots. It came out of the imaging technology, the Professor Emeritus of the University of Alberta explained. In the early 1980s, biotech companies, such as Immunomedics and Cytomedics were researching tumors and using antibodies to image the tumors so they could be evaluated in a cancer patients body. I worked with Dr. Mike Longenecker and we established a company called Biomira (Toronto: BRA) in 1984, Dr. Noujaim recalled. We had a number of targets and then needed to make specific antibodies. Part of his effort was to target certain cancers, such as prostate, breast and ovarian cancer.

We developed antibodies against a mucin, which is really a glycopeptide, explained Dr. Noujaim. Its a peptide that has a lot of sugars on it present in the ascitis fluid from ovarian cancer patients. That is how Dr. Noujaim and his team developed the very early antibody which is now used for OvaRex MAb. We sent some of these antibodies to Professor Richard Baum in Germany for imaging of ovarian cancer patients, Noujaim remembered. Dr. Baum phoned back, after some time, and told me, The patients I was imaging here had advanced ovarian cancer and some of them seem to have done quite well after we gave them a couple of shots (of the B43.13 antibody, the clinical name for OvaRex MAb) to image the tumor. I thought he was joking with me.

This is serendipity at work as Dr. Noujaim explained to us. Richard was imaging patients that were in the last stages of the disease, he pointed out. Monoclonal antibodies can be used as diagnostic agents in oncology, when they are radiolabeled with a marker that can be imaged by external detectors. These patients had maybe four or five months to live. All of a sudden, a year later and theyre still around. Baum urged Noujaim to investigate this further. Dr. Noujaim recalls him saying, Something is happening here. Ive seen hundreds of patients, but nothing like this. From this encouragement, Noujaim began formulating the potential mechanism of how this monoclonal antibody would work. His sharp mind chased the puzzling questions raised by Dr. Baums observations.

At this point of his recollections, Noujaim got excited, Through sheer serendipity, we were using murine antibodies, not humanized antibodies. We were using foreign antibodies, a small amount of foreign antibodies. How in the world did Noujaim know to use murine (mouse) antibodies? Because that was the easiest way to do the imaging at the time, he replied. Before you make a chimeric (something derived from two different animal species) antibody, you start with a murine one. If that one works, you humanize the antibody. From this research, Noujaim founded a company called AltaRex, which was taken public in 1995. We raised about $30 million and expanded the program.

The serious effort to develop the antibodies began in 1996. Having conducted trials in Canada and Europe, it was a massive undertaking Noujaim told us. We had over 500 patients injected with the murine monoclonal antibody. He extrapolated beyond OvaRex MAb, saying, Weve proven completely the mechanism of action on this, how it works. It is so unique it may apply to all of the other antibodies we have. Noujaim believes it can apply to breast, ovarian, prostate and pancreatic cancer. Indeed, BrevaRex MAb for breast cancer and multiple myeloma patients has completed Phase 1 trials, and ProstaRex MAb for prostate cancer patients is at the pre-clinical stage.

Our studies to date may show that vaccines may slow the growth of the tumor with a very good safety profile, concluded Dr. Noujaim. Then he added something which bears investigating further, There is the very original (ovarian cancer) patient who was injected in 1987. Shes in Germany, and according to Dr. Baum she was still alive a year ago. Thats nearly nine years later! Its a matter of great pride for me that some people who received OvaRex MAb are alive today, he said.

While the company has licensed, under a royalty agreement, the OvaRex MAb technology to United Therapeutics, through that companys subsidiary, Unither Pharmaceuticals, ViRexx has retained rights to most member nations of the European Union and certain other countries. Key ones include France, the United Kingdom and the Benelux countries. ViRexx has also established strategic relationships with Domp Farmaceutici, Medison Pharma, Ltd. and Genesis Pharma S.A. for certain European and Middle-East Countries.

Will The President’s Job Bill Hurt Healthcare Jobs

In light of President Obama’s recent speech outlining his plan to create jobs, critics on both sides of the isle question whether or not his plan will be helpful or harmful. Even in unlikely sectors like health care, there is speculation that the Obama bill could be a job killing one. According to industry experts, health care is one of the few sectors that have continued to add jobs despite a persistent economic downturn – about 74,000 in 2010. The problem with the Obama bill is its effect on Medicare and Medicaid.

Impact of Cuts on Healthcare Jobs

Of the previously mentioned is 74,000 healthcare jobs added last year, almost 40% were in the field of assisted living. It is a field which accounts for a fair amount of growth in the overall industry as the American population continues to age. Unfortunately, the vast majority of patients who utilize assisted living do so on Medicare and Medicaid dollars. If the President’s plan is successful in cutting spending for Medicare and Medicaid programs, it could jeopardize the health of many assisted living facilities to the point that they will be forced to close.

Causing further concern is the implementation of universal healthcare beginning in 2014. That law, which was signed back in 2010, may also result in drastic cuts in government medical spending. Hospitals all over the country that depend on government funding for a variety of purposes will have to realign their budgets, forcing them to reduce their workforces. It seems as though a perfect storm may be on the horizon that could spell disaster for the healthcare industry.

The Other Side of the Story

On the other hand, some healthcare industry officials don’t believe the jobs bill will have an effect on healthcare jobs – even if Medicare and Medicaid are cut drastically. They cite the fact that people still need healthcare services, whether or not the government helps them pay for them. Resourceful Americans will find a way to get their healthcare and to make sure it’s paid for. And even in cases when that’s not possible, we are not a nation that allows our people to suffer unnecessarily. As long as there are people, there will be healthcare jobs.

Those who take this view point to countries like Germany and France where governments have realized they need to stop spending so much on healthcare. As a result, private enterprises have begun to spring up to fill in the gaps. And they are hiring.

Despite the potentially bumpy road ahead, health care facilities are continuing to add jobs. As mentioned previously, healthcare is one of the few industries that have continued to grow over the last couple of years, and statistics from the federal labor department indicate that the need for workers will only continue to grow over the next 5 to 10 years. Healthcare jobs will always be available; the only question is what types of jobs they will be. Only time will tell.